Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Pfizer's fortunes overshadow first-quarter dealmaking
Aside from Seagen, small takeouts dominate the first quarter.
The strange battle for Exelixis
A welcome return of shareholder activism sees a curious battle develop for the one-hit wonder Exelixis.
The sun sets on Exelixis’s pipeline in a product
After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.
A renewed push into early bladder cancer
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
Biopharma’s bolt-on bonanza is set to continue
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
JP Morgan 2023 – day one sees buyers make the most of straitened times
Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.